Erik van den Berg
Erik has over 20 years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several biotech companies. Previously, as a senior executive at Organon (now Merck) he was responsible for leading the company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600 million option to acquire AM-Pharma by Pfizer and raised more than €130 million in equity and debt financing. Erik has an MSc in chemistry from the University of Utrecht and an MBA from Manchester Business School, both with honors.